Original synthetic monophenolic antioxidant with combined effect inhibits tumor growth in vivo
Сибирский научный медицинский журнал,
Год журнала:
2025,
Номер
44(6), С. 128 - 137
Опубликована: Янв. 8, 2025
Reactive
oxygen
metabolites
and
antioxidants,
as
well
the
redox-sensitive
signaling
Nrf2-dependent
pathway,
play
a
dual
role
in
formation,
growth
progression
of
malignant
neoplasms.
The
aim
study
was
to
investigate
ability
original
synthetic
monophenolic
antioxidant
combined
action
influence
tumor
vivo
side
effects
cytostatic
use.
Material
methods
.
Lewis
lung
carcinoma
(LLC)
used
an
experimental
model
growth.
performed
on
120
female
C57Bl/6
mice,
which
were
divided
into
12
groups;
animals
weighed
weekly.
Mice
corresponding
groups
received
intragastrically
solution
sodium
3-(3′-
tert
-butyl-4′-hydroxyphenyl)propylthiosulfonate
(TS-13)
(100
mg/kg
body
weight),
suspension
-butylhydroquinone
(tBHQ)
or
solvent
(0.9%
NaCl
solution)
throughout
experiment.
28
days
after
start
TS-13
tBHQ
administration,
mice
implanted
intramuscularly
with
LLC
cells
at
dose
2×10
5
cells/mouse;
7th
14th
development,
doxorubicin
administered
intraperitoneally
twice
cumulative
8
weight
(4/5
LD10).
On
35th
day
growth,
removed
from
experiment,
extracted,
its
linear
dimensions
determined;
mass
coefficient
volume
calculated,
respectively.
spleen
also
estimated.
Results
discussion
receiving
statistically
significantly
greater
than
that
other
carriers.
Administration
inhibited
effectively
doxorubicin,
more
when
combination;
did
not
exert
independent
inhibitory
effect,
enhance
effect
combination
cytostatic.
Doxorubicin
reduced
coefficient,
while
Monotherapy
accompanied
by
hair
loss
dorsal
surface
(8
out
10),
no
alopecia
observed
administration
tBHQ.
Conclusions
Monophenol
TS-13,
direct
inducer
Keap1/Nrf2/ARE
system,
is
comparable
terms
antitumor
effect.
use
allows
reduce
negative
manifestations
associated
chemotherapy,
such
cachexia,
splenotoxity,
alopecia.
Язык: Английский
Metabolism-Related Programmed Cell Death: Unveiling Prognostic Biomarkers, Immune Checkpoints, and Therapeutic Strategies in Ovarian Cancer
Cancer Investigation,
Год журнала:
2025,
Номер
unknown, С. 1 - 22
Опубликована: Апрель 7, 2025
Ovarian
cancer
(OC),
the
gynecologic
malignancy
with
poorest
prognosis,
is
driven
by
metabolic
reprogramming
and
dysregulated
programmed
cell
death
(PCD).
However,
their
interplay
prognostic
significance
remain
inadequately
understood.
Transcriptomic
data
from
OC
patients
healthy
controls
(TCGA
GTEx)
were
analyzed
to
identify
differentially
expressed
genes
(DEGs)
intersecting
metabolism-related
(MRGs)
PCD-related
(PCDRGs).
Prognostic
determined
using
univariate
Cox
regression,
LASSO,
multivariate
stepwise
analyses.
Consensus
clustering
revealed
enrichment
differences,
while
a
risk
model
nomogram
developed
for
outcome
prediction.
Associations
between
genes,
immune
microenvironment,
drug
sensitivity
also
assessed.
A
total
of
166
candidate
identified,
PLA2G2D,
LPCAT3,
ARG1,
PLA2G4A,
EXOSC3
emerging
as
significant
markers.
The
demonstrated
marked
survival
showed
robust
calibration
Differential
infiltration
was
observed
groups.
Additionally,
Sinularin
Fulvestrant
exhibited
variable
sensitivity,
validated
through
molecular
docking
models.
Metabolism-related
PCD
identified
pivotal
markers
in
OC,
providing
critical
insights
evaluation
targeted
therapy
development.
Язык: Английский